Galderma has launched its next-generation skincare innovation, Regenerating Skin Nectar with TriHex+, under its Alastin brand. The company positions the product as an advanced peri-procedural skincare solution designed to enhance skin preparation and recovery around cosmetic treatments.
The new launch builds on the original Regenerating Skin Nectar, which has been widely used in aesthetic dermatology for over a decade. Dermatologists commonly recommend it before and after procedures such as laser resurfacing, chemical peels, microneedling, facelifts, and radiofrequency treatments. The earlier formulation established itself as a category-defining product in peri-procedural skincare.
Introduction of TriHex+ technology platform
The company says the formulation aims to further improve how skin prepares for, responds to, and recovers from aesthetic procedures. It continues to focus on supporting visible improvements in skin quality and resilience.
The innovation is part of the Alastin skincare portfolio, which specialises in peptide-based regenerative skincare solutions. The brand has built its reputation on clinically tested products that support skin healing and structural improvement.
Supports collagen and elastin renewal
According to the company, Regenerating Skin Nectar with TriHex+ enhances the skin’s natural ability to remove damaged collagen and elastin. It also supports the production of new structural proteins, including collagen, elastin, and high-molecular-weight hyaluronic acid. This dual-action approach is designed to strengthen the skin’s underlying framework.
The upgraded formula also includes a proprietary peptide, Octapeptide-45, which expands the original TriHex Technology system. This addition helps support skin barrier function and improves overall skin recovery after cosmetic procedures.
Designed for post-procedure skin sensitivity
The company highlights that the product is water-free, preservative-free, and bacteriostatic. These features allow use immediately after aesthetic procedures when skin is most sensitive. This makes it suitable for early-stage post-procedure care without causing irritation.
Regenerating Skin Nectar with TriHex+ is the second product to feature the new TriHex+ platform. It follows the earlier launch of Restorative Skin Complex with the same upgraded technology.
Clinical backing and physician adoption
Galderma emphasises that the product is supported by clinical studies and physician adoption. Dermatologists have long used the original Skin Nectar as a pre-conditioning step to improve treatment outcomes and reduce downtime.
The company states that the updated formulation strengthens its commitment to science-driven dermatology innovation. It focuses on improving procedural outcomes while supporting long-term skin health and recovery.
Clinical evidence cited by Galderma shows improvements in skin hydration, barrier function, and extracellular matrix markers. These include collagen, elastin, and hyaluronic acid levels after controlled studies.
The product also supports improvements in dermal-epidermal junction integrity. This structural layer plays a key role in how skin responds to mechanical and thermal stress during cosmetic procedures.
Global rollout strategy
The company plans to initially distribute the product through authorised aesthetic practitioners. These include dermatology clinics, plastic surgery offices, and medical spas.
The company is also working to expand availability to additional international markets where Alastin products are already present. This expansion aligns with its broader strategy to grow itThe launch reinforces Galderma’s position in the growing peri-procedural skincare segment. The company continues to invest in peptide-based innovations that target skin regeneration and recovery.
With this introduction, the firm aims to offer dermatologists and patients more advanced tools for improving cosmetic procedure outcomes. The focus remains on enhancing skin resilience, accelerating recovery, and delivering more consistent aesthetic results.
Also read: Galderma highlights dermatology evidence at AAD 2026